Company Profile

Adaptive Phage Therapeutics Inc (AKA: APT)
Profile last edited on: 10/11/2022      CAGE: 7W7L6      UEI: PWCMZJMBSNK6

Business Identifier: Therapeutic services treating multi-drug resistant pathogenic bacteria.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

708 Quince Orchard Road Suite 205
Gaithersburg, MD 20878
   (844) 972-0500
Location: Single
Congr. District: 06
County: Montgomery

Public Profile

Adaptive Phage Therapeutics (APT) is a clinical-stage company structured around providing an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria. Designed to provide a unique capability to adapt to the emergence of future antibiotic-resistant superbugs, Adaptive Phage Therapeutics bank’s precision targeted, genomically screened, and highly purified phage collection is dynamically expanding in response to the emergence of new strains of bacterial superbugs. The company is developing phage-based therapies designed to target specific bacteria strains -- as contrasted with antibiotics, which target multiple types of bacteria. In January it was announced that the firm was in receipt of a non-SBIR DOD contract inthe amount of $10M for development of antibacterial phage therapies: Phages are viruses that infect and kill bacteria, and APT’s scientific rationale is based on the fact that, in general, a single phage strain can only infect a single bacterial strain. According to the firm's web page, Adapative Phage uses genomic screening and purification of phages in its collection, identifying additional phages to use if bacteria develop resistance to them. By contrast, antibiotic drugs target multiple types of bacteria, but in recent years a growing number of drug-resistant strains have emerged.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2021 1 NIH $296,787
Project Title: Development of a Rapid and Scalable Method for Bacteriophage Manufacture and Purification

Key People / Management

  Greg Merril -- Co-Founder and Chief Executive Office

  Subhendu Basu -- President and COO

  Michael Billard -- Business Contact

  Mike Orndorff -- Vice President, Finance and Administration

Company News

There are no news available.